- Home
- AMGN vs DHR Comparison
AMGN vs DHR Comparison
Compare AMGN & DHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMGN
- DHR
- Stock Information
- Founded
- AMGN 1980
- DHR 1969
- Country
- AMGN United States
- DHR United States
- Employees
- AMGN N/A
- DHR N/A
- Industry
- AMGN Biotechnology: Biological Products (No Diagnostic Substances)
- DHR Industrial Machinery/Components
- Sector
- AMGN Health Care
- DHR Industrials
- Exchange
- AMGN Nasdaq
- DHR Nasdaq
- Market Cap
- AMGN 155.9B
- DHR 135.4B
- IPO Year
- AMGN N/A
- DHR N/A
- Fundamental
- Price
- AMGN $295.27
- DHR $204.70
- Analyst Decision
- AMGN Hold
- DHR Strong Buy
- Analyst Count
- AMGN 20
- DHR 18
- Target Price
- AMGN $322.30
- DHR $263.00
- AVG Volume (30 Days)
- AMGN 2.7M
- DHR 3.6M
- Earning Date
- AMGN 08-05-2025
- DHR 07-22-2025
- Dividend Yield
- AMGN 3.22%
- DHR 0.62%
- EPS Growth
- AMGN 56.16
- DHR N/A
- EPS
- AMGN 10.94
- DHR 5.16
- Revenue
- AMGN $34,126,000,000.00
- DHR $23,820,000,000.00
- Revenue This Year
- AMGN $7.73
- DHR $3.63
- Revenue Next Year
- AMGN $1.68
- DHR $6.45
- P/E Ratio
- AMGN $27.00
- DHR $39.72
- Revenue Growth
- AMGN 15.56
- DHR 0.35
- 52 Week Low
- AMGN $253.30
- DHR $171.00
- 52 Week High
- AMGN $346.85
- DHR $281.70
- Technical
- Relative Strength Index (RSI)
- AMGN 55.95
- DHR 59.41
- Support Level
- AMGN $291.25
- DHR $197.12
- Resistance Level
- AMGN $302.38
- DHR $208.15
- Average True Range (ATR)
- AMGN 8.76
- DHR 4.77
- MACD
- AMGN 1.17
- DHR 0.35
- Stochastic Oscillator
- AMGN 79.42
- DHR 77.39
About AMGN Amgen Inc.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
About DHR Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Then, through a series of mergers, acquisitions, and divestitures, Danaher now focuses primarily on manufacturing scientific instruments and consumables in the life science and diagnostic industries after the late 2023 divestiture of its environmental and applied solutions group, Veralto.